TIZANIDINE Drug Interactions
Also known as: Tizanidine
Tizanidine is a medication used to relax muscles and reduce muscle stiffness or spasms (spasticity). It works by acting on the nervous system to calm overactive nerve signals that cause muscles to tighten. This helps improve muscle movement and comfort for daily activities.TIZANIDINE has 10 documented drug interactions in our database, including 0 contraindicated, 10 major, 0 moderate, and 0 minor interactions.
0
Contraindicated
10
Major
0
Moderate
0
Minor
Patients may experience increased sedation, somnolence, dizziness, and psychomotor impairment. The most serious clinical effect is an enhanced risk of respiratory depression, which can be life-threatening. Other effects include hypotension and profound bradycardia.
Mechanism
Buprenorphine, a partial opioid agonist, exerts its analgesic and CNS depressant effects primarily through mu-opioid receptor agonism. Tizanidine, an alpha-2 adrenergic agonist, reduces spasticity by increasing presynaptic inhibition of motor neurons in the spinal cord, which also leads to CNS depression. The co-administration of these two agents results in additive CNS depression.
Clinical Management
Concomitant use should generally be avoided due to the high risk of additive CNS and respiratory depression. If co-administration is unavoidable, initiate both medications at lower doses and titrate cautiously, monitoring closely for signs of sedation and respiratory compromise. Educate patients about the risks and advise against operating heavy machinery or driving.
Patients may experience severe respiratory depression, characterized by decreased respiratory rate and depth, potentially leading to hypoxemia and hypercapnia. Other clinical effects include profound sedation, excessive somnolence, dizziness, impaired psychomotor function, and hypotension. This combination significantly increases the risk of falls, accidental injury, and life-threatening respiratory compromise.
Mechanism
Both fentanyl, an opioid agonist, and tizanidine, an alpha-2 adrenergic agonist muscle relaxant, exert significant central nervous system (CNS) depressant effects. Their co-administration leads to an additive pharmacological effect, increasing the overall CNS depression. This synergistic action primarily affects neuronal excitability and neurotransmitter release, leading to profound sedation and respiratory depression.
Clinical Management
Concomitant use should generally be avoided due to the high risk of severe adverse effects. If co-administration is unavoidable, initiate both medications at the lowest effective doses and titrate cautiously while closely monitoring for signs of respiratory depression and sedation. Educate patients and caregivers on the symptoms of CNS depression and advise against operating heavy machinery or driving. Consider alternative non-opioid analgesics or non-pharmacological muscle relaxants if possible.
Patients may experience increased sedation, respiratory depression, dizziness, confusion, and impaired psychomotor function. This can lead to an increased risk of falls, accidental injury, and potentially life-threatening hypoventilation or respiratory arrest. The effects can be more pronounced in elderly patients or those with pre-existing respiratory compromise.
Mechanism
Oxycodone is an opioid agonist that produces central nervous system (CNS) depression by binding to mu-opioid receptors. Tizanidine is an alpha-2 adrenergic agonist that also causes CNS depression and muscle relaxation through central mechanisms. The co-administration of these agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of oxycodone and tizanidine if possible. If co-administration is unavoidable, initiate both medications at the lowest effective doses and titrate slowly while closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks and advise them to avoid driving or operating heavy machinery. Consider alternative non-opioid analgesics or non-pharmacological muscle relaxants if appropriate.
Patients may experience profound sedation, respiratory depression, hypotension, dizziness, confusion, and impaired psychomotor function. This can lead to an increased risk of falls, accidental injury, and life-threatening respiratory compromise. The risk is heightened in elderly patients or those with pre-existing respiratory conditions.
Mechanism
Both morphine, an opioid analgesic, and tizanidine, an alpha-2 adrenergic agonist muscle relaxant, are central nervous system (CNS) depressants. Their co-administration leads to an additive depressant effect on the CNS, enhancing sedation and respiratory depression. Tizanidine also has hypotensive effects that can be additive with opioids.
Clinical Management
Avoid concurrent use of morphine and tizanidine if possible. If co-administration is unavoidable, start with lower doses of both medications and titrate carefully, monitoring closely for signs of CNS and respiratory depression. Educate patients on the risks and advise against driving or operating heavy machinery.
Patients may experience profound sedation, dizziness, confusion, and impaired psychomotor function. This additive CNS depression significantly increases the risk of respiratory depression, hypotension, and falls. In severe cases, it can lead to coma or death.
Mechanism
Both tramadol and tizanidine cause central nervous system (CNS) depression. Tramadol exerts its analgesic effect through opioid receptor agonism and inhibition of norepinephrine and serotonin reuptake, contributing to CNS depression. Tizanidine is an alpha-2 adrenergic agonist that reduces spasticity by increasing presynaptic inhibition of motor neurons in the spinal cord, also leading to significant CNS depression. The concurrent use results in an additive depressant effect on the CNS.
Clinical Management
Avoid concurrent use of tramadol and tizanidine if possible. If co-administration is unavoidable, initiate both medications at the lowest effective doses and titrate cautiously while closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks and advise against operating machinery or driving until the effects are known.
Patients may experience increased sedation, dizziness, confusion, and psychomotor impairment. The most serious clinical effect is an enhanced risk of respiratory depression, which can be life-threatening. Other effects include profound drowsiness, hypotension, and impaired coordination.
Mechanism
Codeine sulfate is an opioid analgesic that exerts its effects by agonizing mu-opioid receptors in the central nervous system, leading to CNS depression, analgesia, and respiratory depression. Tizanidine is an alpha-2 adrenergic agonist that reduces spasticity primarily by increasing presynaptic inhibition of motor neurons at the spinal cord level, also causing significant CNS depression. The co-administration of these agents results in an additive depressant effect on the central nervous system.
Clinical Management
Avoid concomitant use of codeine and tizanidine if possible. If co-administration is necessary, initiate both medications at the lowest effective dose and titrate slowly while closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks and advise them to avoid driving or operating heavy machinery. Consider alternative non-opioid analgesics or non-pharmacological treatments for pain.
Patients may experience profound sedation, somnolence, dizziness, and impaired psychomotor function. The most serious clinical effect is an increased risk of respiratory depression, which can be life-threatening. Hypotension and bradycardia may also occur due to additive effects on the cardiovascular system.
Mechanism
Methadone, an opioid agonist, and tizanidine, an alpha-2 adrenergic agonist muscle relaxant, both exert significant central nervous system (CNS) depressant effects. Their co-administration leads to an additive pharmacological effect, increasing the overall level of CNS depression. This synergistic action primarily affects neuronal excitability and neurotransmission in the brain and spinal cord.
Clinical Management
Avoid concomitant use of methadone and tizanidine if possible. If co-administration is unavoidable, initiate both medications at the lowest effective doses and titrate cautiously. Closely monitor patients for signs of respiratory depression, excessive sedation, and changes in mental status, especially during initiation or dose adjustments. Educate patients about the risks and advise against operating heavy machinery or driving.
Patients may experience profound sedation, respiratory depression (ranging from mild to life-threatening), hypotension, and psychomotor impairment. This can lead to decreased level of consciousness, dizziness, extreme drowsiness, and impaired coordination, increasing the risk of falls and accidents.
Mechanism
Both hydromorphone, an opioid agonist, and tizanidine, an alpha-2 adrenergic agonist, exert significant central nervous system (CNS) depressant effects. When co-administered, their individual depressant actions on the brain are additive, leading to an enhanced overall CNS depression.
Clinical Management
Avoid concomitant use if possible. If co-administration is necessary, initiate both drugs at the lowest effective doses and titrate slowly while closely monitoring for signs of CNS and respiratory depression. Educate patients about the risks and advise against driving or operating heavy machinery.
Patients may experience severe sedation, profound respiratory depression, coma, and even death. Other potential effects include impaired psychomotor function, dizziness, confusion, and hypotension, which can increase the risk of falls and accidents.
Mechanism
Oxymorphone is an opioid agonist that produces central nervous system (CNS) depression through its action on mu-opioid receptors. Tizanidine is an alpha-2 adrenergic agonist that also causes significant CNS depression, muscle relaxation, and sedation. The co-administration of these two agents results in an additive depressant effect on the CNS.
Clinical Management
Avoid concomitant use of oxymorphone and tizanidine due to the high risk of additive CNS and respiratory depression. If co-administration is unavoidable, reduce the starting dose of one or both medications, monitor patients closely for signs of sedation and respiratory depression, and educate them on the risks. Consider alternative non-opioid analgesics or non-pharmacological treatments for pain or muscle spasms.
Patients may experience profound sedation, dizziness, confusion, respiratory depression, hypotension, and psychomotor impairment. This can significantly increase the risk of falls, accidental injury, and life-threatening respiratory compromise.
Mechanism
Both tapentadol, an opioid analgesic, and tizanidine, a centrally acting alpha-2 adrenergic agonist muscle relaxant, cause central nervous system (CNS) depression. The co-administration of these agents results in an additive depressant effect on the CNS, leading to enhanced sedation and respiratory depression.
Clinical Management
Avoid concomitant use of tapentadol and tizanidine due to the high risk of additive CNS and respiratory depression. If co-administration is unavoidable, reduce the dosage of one or both drugs, monitor patients closely for signs of CNS depression and respiratory compromise, and educate them on the risks.
For complete prescribing information:
View full TIZANIDINE monograph →Medical Disclaimer
The information on RxGuide is intended for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, pharmacist, or other qualified health provider with any questions you may have regarding a medical condition or medication. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.